Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $69.4900 (1.92%) ($68.0600 - $69.7400) on Wed. Sep. 11, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.47% (three month average) | RSI | 57 | Latest Price | $69.4900(1.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV advances 0.9% a day on average for past five trading days. | Weekly Trend | ABBV advances 1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(63%) DIA(52%) SPLV(52%) VYM(52%) IVE(51%) | Factors Impacting ABBV price | ABBV will decline at least -1.235% in a week (0% probabilities). VIXM(-36%) VXX(-15%) TLT(-14%) IGOV(-3%) UUP(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.235% (StdDev 2.47%) | Hourly BBV | 0 () | Intraday Trend | 1.9% | | | |
|
5 Day Moving Average | $67.8(2.49%) | 10 Day Moving Average | $66.95(3.79%) | 20 Day Moving Average | $66.36(4.72%) | To recent high | -12% | To recent low | 10.3% | Market Cap | $122.6b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |